Velaglucerase Alfa
Mechanism :
Velaglucerase alfa, which contains the same amino acid sequence as endogenous glucocerebrosidase, catalyzes the hydrolysis of glucocerebroside to glucose and ceramide in the lysosome. Velaglucerase alfa is used to diminish hepatosplenomegaly and improve anemia, thrombocytopenia, and bone disease.
Indication :
Contraindications :
There are no contraindications listed.
Dosing :
IV:
60 units/kg administered every 2 weeks.
Adverse Effect :
Headache, dizziness, fatigue, weakness, abdominal pain, prolonged partial thromboplastin time, hypersensitivity reaction, back pain, arthralgia, fever.
Interaction :
There are no known significant interactions.
Hepatic Dose :
No dose adjustment recommended.